All stock lists
Royalty Pharma plc (NASDAQ:RPRX)
US · Delayed Price · Currency is USD
Healthcare · Medical - Pharmaceuticals
64.41+0.55 (+0.86%)
Market cap
$28.7B
Health Score
Analyst consensus
Listed since
Jun 16, 2020
Website
Insider Score
––Not scored
RPRX Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
RPRX analyst forecast
RPRX analyst consensus
Moderate Buy3 ratings
Buy 3 Hold 0 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
RPRX 12-month price target
No published price targets in the last 12 months.
Best analysts covering RPRX
- Citigroup100%success rate · 3 calls
- JP Morgan33%success rate · 3 calls
- Morgan Stanley31%success rate · 13 calls
- UBS0%success rate · 2 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
RPRX analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-10-07 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-09-08 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-08-07 |
| — | TD Cowen | Buy | — | — | Reiterated | 2026-07-13 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2026-05-07 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-05-07 |
| — | UBS | Buy | — | — | Reiterated | 2026-04-21 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2026-04-10 |
| — | UBS | Buy | — | — | Upgraded | 2026-01-30 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-01-27 |
| — | TD Cowen | Buy | — | — | Reiterated | 2025-12-11 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-10-10 |
| — | Citigroup | Buy | — | — | Reiterated | 2025-07-22 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2025-07-10 |
| — | Citigroup | Buy | — | — | Reiterated | 2024-10-25 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2024-08-14 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2024-07-11 |
| — | UBS | Neutral | — | — | Downgraded | 2024-06-03 |
| — | B of A Securities | Buy | — | — | Reiterated | 2024-04-12 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2024-02-20 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2024-02-20 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2023-11-09 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2023-10-11 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2023-08-09 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2023-07-11 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2023-05-10 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2023-04-10 |
| — | Tigress Financial | Buy | — | — | Reiterated | 2023-04-06 |
| — | UBS | Buy | — | — | Reiterated | 2023-02-16 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2022-12-06 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2022-11-09 |
| — | JP Morgan | Overweight | — | — | Reiterated | 2022-10-18 |
| — | Scotiabank | Outperform | — | — | Reiterated | 2022-09-13 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2022-08-08 |
| — | Tigress Financial | Buy | — | — | Reiterated | 2022-07-14 |
| — | UBS | Buy | — | — | Reiterated | 2022-06-14 |
| — | Scotiabank | Outperform | — | — | Reiterated | 2022-05-13 |
| — | Goldman Sachs | Buy | — | — | Reiterated | 2022-04-27 |
| — | JP Morgan | Overweight | — | — | Upgraded | 2022-04-14 |
| — | Morgan Stanley | Overweight | — | — | Upgraded | 2022-04-06 |
| — | Citigroup | Buy | — | — | Upgraded | 2021-10-29 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2021-08-16 |
| — | Tigress Financial | Buy | — | — | Reiterated | 2021-07-30 |
| — | UBS | Buy | — | — | Upgraded | 2020-11-09 |
| — | B of A Securities | Buy | — | — | Reiterated | 2020-07-13 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2020-07-13 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2020-07-13 |
| — | SunTrust Robinson Humphrey | Buy | — | — | Reiterated | 2020-07-13 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2020-07-13 |
RPRX earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-11 | 1.29 | 1.46 | $807.0M | $874.0M |
| 2026-05-06 | 1.21 | 1.30 | $881.7M | $925.0M |
| 2026-08-05 | 1.27 | 1.32 | $758.9M | $773.0M |
| 2026-11-04 | 1.18 | 0.00 | $884.8M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.